Today's Peptide News — August 16, 2026

Novo Nordisk has moved both oral and subcutaneous formulations of amycretin, its long-acting molecule that activates the GLP-1 and amylin receptors simultaneously, into Phase 3 testing for adults with overweight or obesity after positive regulatory feedback. The dual mechanism pairs the appetite-suppressing GLP-1 pathway with amylin signaling, which slows gastric emptying and reinforces satiety, and is being positioned as a potential successor to semaglutide. That an oral version is advancing alongside the injectable is notable, because bringing a peptide into a pill that survives the gut has been one of the field's hardest problems.

The move matters because it deepens a shift away from single-hormone GLP-1 drugs toward combinations that hit two or more metabolic receptors, a strategy that has consistently produced larger weight loss in trials. It also intensifies the head-to-head race with Eli Lilly, whose own multi-receptor agonists are posting record numbers. For PeptideWiki, a short post on amycretin can explain what a GLP-1/amylin dual agonist is, how it differs from semaglutide and tirzepatide, and why the oral formulation is a milestone for peptide drug delivery.

A bioRxiv preprint combines a generative deep-learning model with atomistic molecular dynamics simulations to work out the design rules for antimicrobial peptides that fold into amyloid-like structures. Rather than screening natural sequences, the model was trained on both antimicrobial and amyloid-forming peptides and used to generate new candidates, with the simulations then explaining which structural features drive membrane disruption and self-assembly. The result is a set of interpretable principles linking sequence, aggregation behavior, and antibacterial potency.

This is worth a post because antimicrobial peptides are one of the most promising routes around conventional antibiotic resistance, and generative AI is rapidly becoming the dominant way to design them. The angle for PeptideWiki: explain how amyloid-like self-assembly, usually thought of as a disease-causing nuisance, can be deliberately engineered into a bacteria-killing feature, and how AI plus physics simulation is speeding up the discovery of peptides that would take years to find by hand.

GLP-1 receptor agonists such as semaglutide appear to do more than blunt hunger — new work traces part of their effect to the lateral septum, a deep brain region that links memory, emotion, and reward. Researchers report that these drugs dampen activity in this hub in a way that reduces cravings not only for food but potentially for alcohol and other addictive substances, offering a mechanistic explanation for the anecdotal and clinical reports that GLP-1 users drink and smoke less.

The finding matters because it reframes GLP-1 peptides as neuromodulators of reward circuitry rather than purely metabolic drugs, which could open formal indications in addiction medicine. A PeptideWiki post could walk through how a gut-hormone-mimicking peptide reaches and influences a specific brain region, and why that positions semaglutide and its successors as candidates for treating cravings well beyond appetite.

A second bioRxiv preprint tackles antimicrobial peptide discovery from the prediction side, layering sequence-level features together with structural information in a single multi-scale model. By integrating what a peptide's amino acid string implies with how it is predicted to fold, the approach improves the accuracy of separating genuinely antimicrobial peptides from inactive look-alikes and guides the design of new active sequences. It reflects a broader trend of fusing language-model-style sequence learning with structure prediction tools.

For PeptideWiki, this pairs naturally with the generative amyloid-peptide work above as a two-part look at how computation is reshaping antimicrobial peptide research: one preprint generates candidates, the other screens and ranks them. A short post could explain why combining sequence and structure beats either signal alone, and what that means for the pace at which new antibiotic-resistant-bug fighters can reach the lab bench.

Alveus Therapeutics emerged from stealth with roughly $160 million in venture funding to advance an obesity peptide that engages the GLP-1, GIP, and amylin pathways, echoing the multi-receptor design strategy behind Amgen's MariTide. The sizable raise signals that investors still see room for new entrants in the obesity market despite the dominance of Novo Nordisk and Eli Lilly, betting that a differentiated receptor combination can carve out clinical or dosing advantages.

The news is relevant to peptide watchers because it shows the obesity pipeline broadening beyond the two incumbents and doubling down on amylin as the ingredient of choice for next-generation combinations. A PeptideWiki angle: use Alveus as a hook to explain why amylin has become the hot add-on receptor, and how a startup with a single peptide program can attract nine-figure funding in a field this crowded.

CagriSema, Novo Nordisk's fixed combination of the GLP-1 agonist semaglutide and the long-acting amylin analog cagrilintide, delivered 22.7% average weight loss at 68 weeks in the REDEFINE 1 trial, outperforming semaglutide alone and keeping the program on track for an FDA filing expected in late 2026. The two-peptide combination is one of the clearest demonstrations that stacking an amylin analog on top of GLP-1 produces additive weight loss, and it remains a benchmark against which newer dual-agonist molecules are measured.

This matters as a real-world validation of the amylin-plus-GLP-1 thesis that underpins amycretin, Alveus, and much of the current pipeline. For PeptideWiki, cagrilintide deserves its own explainer: what an amylin analog is, how combining two separate peptides differs from engineering a single dual agonist, and why CagriSema's numbers set the bar for the combinations now entering late-stage trials.

Researchers report that a single, one-time combination of three therapies eliminated HIV in newborn nonhuman primates when given within three days of infection. The approach cleared detectable virus in treated animals, raising the possibility of a functional cure administered very early rather than a lifetime of daily antiretroviral therapy, and pointing toward strategies to stop mother-to-child transmission at the source.

The result is significant because durable clearance, not just suppression, has been the elusive goal of HIV research for decades, and doing it with a single early intervention in a primate model is a meaningful step. While the therapy combination is not primarily peptide-based, it is a standout health-science headline of the week and a reminder of how combination biologics are reshaping infectious-disease treatment.

Scientists have found that the gene TBX5, long linked to congenital heart disease, acts like an architect for the three-dimensional folding of a heart cell's genome. Losing just one of the two copies of TBX5 was enough to unravel the carefully organized 3D structure of the DNA, disrupting the coordinated activity of the genes a developing heart needs and helping explain how a single faulty gene copy can cause structural heart defects.

The finding matters because it connects a well-known disease gene to the physical architecture of the genome, a layer of biology that is only now becoming visible. It suggests that some congenital conditions arise not from a broken protein but from misfiled genetic instructions, a perspective that could eventually inform how such defects are diagnosed and understood.

A protein inside the brain's appetite-controlling neurons appears to act as a brake on overeating, and it is especially important when high-fat foods are freely available. In animal experiments, the protein helped these neurons resist the pull of energy-dense food, and unexpected differences between males and females hinted at why the sexes can respond differently to the same diet and to obesity risk.

The work is relevant because it locates part of the biology of overeating inside a specific, drug-targetable neuronal protein rather than in willpower or environment alone. It also sits alongside this week's GLP-1 brain findings as evidence that appetite is governed by identifiable molecular switches, some of which could become targets for future weight-management therapies.

A study found that regularly drinking orange juice was associated with changes in the expression of thousands of genes, including many tied to inflammation, blood pressure, metabolism, and blood-cell function. Rather than acting through a single nutrient, the juice appeared to nudge broad networks of gene activity, suggesting its effects on the body may be more systemic than previously assumed.

The finding is a useful reminder that everyday foods can leave a measurable molecular signature, and that some of the health associations attributed to diet may operate through gene regulation. As an observational nutrition result it stops short of proving cause and effect, but it adds to the growing picture of how common beverages interact with human biology at the level of the genome.